Another meta-analysis of the same seven trials similarly reported that GLP-1RAs significantly reduced MACE, with a number needed to treat (NNT) to prevent one MACE of 73 (95% CI 45212) ( Reasons that have been postulated to account for the lack of positive effect in the ELIXA trial are the different trial populations (such that biological processes after an acute coronary event may be less amenable to modification than those relating to general atherosclerosis) and the short duration of action of lixisenatide (insufficient GLP-1 receptor stimulation over the 24-hour dosing period) ( What Is the Place of GLP-1RAS in the Guidelines for Patients With Diabetes and Cardiovascular Disease
Adam Wolfe, an internal medicine specialist with University of Michigan Health-West Hospital, told Fox News Digital in an interview
Clinical trials (SURPASS for type 2 diabetes and SURMOUNT for obesity) have demonstrated substantial weight reduction in people taking tirzepatide, with weight loss varying by indication, dose, and population
In McKenzies case, Jack prescribed the weight-loss drug Wegovy, which in late 2022 was approved for use in U.S
However, once reconstituted with bacteriostatic water , the clock starts immediately
